Key statistics dashboard for GT Biopharma, Inc. (GTBP). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells.
Stock Data
| Price | $7.81 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.09 |
| Price / Book | 3.92 |
| P/S | 0.00 |
| P/FCF | -0.79 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 2.61 |
| Quick Ratio | 2.61 |
| Cash Ratio | 2.24 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | -128.64 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -128.11 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 2.30 |
| Cash per share | 3.19 |
| FCF per share | -9.29 |
| Tangible Book Value per share | 2.30 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 5 |
| Avg rating (1-5) | 0.80 |
Related companies: ARTL · CARM · DRMA · LIPO · PBM · PTIX · REVB
Explore sector: Healthcare · Biotechnology
More sections of GTBP: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks